Clinical trials: Migraine, Acute
Migraine Headache
A Study on the Usability of the Needle-free Intraject® System in Adult Patients During Acute Migraine Attack
Intraject is a needle-free, single use, disposable, subcutaneous delivery system pre-filled with 6mg Sumatriptan to be used by patients to treat acute migraine treatment.
- Trial name
- NCT00530517
- Testing
- Intraject Sumatriptan
- Where
- 4 sites in United States
- Volunteers
- 54 people
- Sponsor
- Zogenix, Inc.
Acute Migraine With or Without Aura
Study to Assess the Safety and Efficacy of ONZETRA® Xsail® for the Acute Treatment of Episodic Migraine With or Without Aura in Adolescents
This study will be conducted to evaluate the safety and efficacy of sumatriptan nasal powder (AVP-825) compared to placebo in the acute treatment of migraine in adolescent participants, 12 through 17 years of age.
- Trial name
- NCT03338920
- Testing
- sumatriptan nasal powder
- Where
- 40 sites in United States
- Volunteers
- 159 people
- Sponsor
- Currax Pharmaceuticals
Migraine, Classic Migraine
Potential Impact (Benefit) of Preventative Treatment With Topamax on the Effectiveness of Axert in the Acute Treatment of Migraine
The purpose of this study is to evaluate the impact of topiramate (migraine prevention medicine) on the effectiveness of almotriptan malate (acute migraine medicine) when treating acute migraine headaches.
- Conditions
- Migraine, Classic Migraine, Common Migraine
- Trial name
- NCT00210496
- Testing
- topiramate; almotriptan malate
- Volunteers
- 406 people
- Sponsor
- Janssen-Ortho LLC
Migraine
Post-marketing Clinical Trial of Elexir(Trigeminal Nerve Electrical Stimulator) for the Acute Treatment of Migraine
The purpose of this study is to evaluate the efficacy and safety of treating migraine in the acute phase by applying the acute mode (program 1) of Elexir (trigeminal nerve electrical stimulator) to patients with migraine.
- Trial name
- NCT06170411
- Testing
- Elexir (program1)
- Where
- 2 sites in South Korea
- Volunteers
- 100 people
- Sponsor
- Nu Eyne Co., Ltd.
Migraine
A Double Blind Placebo-controlled, Parallel Group Study to Assess the Efficacy and Safety of Frovatriptan in the Acute Treatment of Migraine
The purpose of this study is: 1. To compare the efficacy of a single dose of Frovatriptan 2.5 mg with that of placebo in acute treatment of up to one migraine attract 2. To assess recurrence rate between two group 3.
- Trial name
- NCT00821483
- Testing
- Frovatriptan
- Volunteers
- 298 people
- Sponsor
- SK Chemicals Co., Ltd.
Acute Migraine
Long-term Safety Study of BHV-3500 (Zavegepant*) for the Acute Treatment of Migraine
The purpose of this study is to evaluate the long-term safety of BHV-3500/vazegepant intranasal in the acute treatment of migraine. BHV-3500, formerly "vazegepant", is now referred to as "zavegepant" (za ve' je pant).
- Trial name
- NCT04408794
- Testing
- Zavegepant (BHV-3500)
- Where
- 67 sites in United States
- Volunteers
- 974 people
- Sponsor
- Pfizer
Acute Treatment of Migraine
A Study to Find Out if the Medicine Called Rimegepant is Safe for Adults in India
This is a multicenter, single-arm, open-label Phase 4 study evaluating the safety and tolerability of rimegepant 75 mg orally disintegrating tablet (ODT) for the acute treatment of migraine (with or without aura) in adult…
- Trial name
- NCT07685769
- Testing
- Rimegepant 75 mg ODT
- Where
- 7 sites in India
- Volunteers
- 60 people
- Sponsor
- Pfizer
Migraine, Chronic Migraine
Eptinezumab as an Adjunct to Standard of Care for Migraine in an Acute Emergency Context
The purpose of the study is to investigate how a medication called eptinezumab (Vyepti) given to patients in the Emergency Department (ED) might help prevent migraines from happening again.
- Trial name
- NCT06428838
- Testing
- Eptinezumab, Standard of Care
- Where
- 2 sites in Canada
- Volunteers
- 102 people
- Sponsor
- Dr George Medvedev
Migraine, Migraine With or Without Aura
Evaluation of a Wearable Device for Acute Treatment of Migraines
The goal of this clinical trial is to determine the efficacy of a new, improved neuromodulation device that can be worn on the head and neck to relieve migraine pain.
- Conditions
- Migraine, Migraine With or Without Aura, Migraine, Acute, Migraine Headache
- Trial name
- NCT07015125
- Testing
- Transcutaneous Electrical Nerve Stimulation (TENS)
- Where
- United States
- Volunteers
- 160 people
- Sponsor
- Hinge Health, Inc
Migraine
MK3207 for Treatment of Acute Migraines (3207-005)
The purpose of the study is to demonstrate the effectiveness and appropriate dosage level of MK3207 in the treatment of acute migraine.
- Trial name
- NCT00712725
- Testing
- MK3207- 2.5 mg, MK3207- 5 mg, MK3207- 10 mg
- Volunteers
- 676 people
- Sponsor
- Merck Sharp & Dohme LLC
Migraine Disorders
A Study of Lasmiditan in Participants With Migraine
The purpose of this study is to measure how much of the drug gets into the blood stream and how long it takes the body to get rid of it during an acute migraine attack and also during the time between acute migraine attacks.
- Trial name
- NCT03247790
- Testing
- Lasmiditan
- Where
- 3 sites in United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Migraine With or Without Aura
Efficacy, Safety, and Tolerability of Oral Eletriptan for Treatment of Acute Migraine
To confirm the efficacy of three dose levels of oral eletriptan relative to placebo in relieving symptoms of acute migraine and to further explore the dose response relationship of eletriptan.
- Trial name
- NCT01978496
- Testing
- Eletriptan 20 mg, Eletriptan 40 mg, Eletriptan 80 mg
- Volunteers
- 1,334 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Migraine, Headache
Efficacy and Safety of a Fixed-dose Combination of Naratriptan and Naproxen in Acute Treatment of Migraine.
The purpose of this study is to determine whether a fixed-dose combination of naratriptan 2,5 mg + naproxen 500 mg is effective and safe compared each monotherapy for the acute treatment of migraine.
- Trial name
- Copérnico (NCT01726920)
- Testing
- naratriptan + naproxen, naratriptan, naproxen
- Sponsor
- Ache Laboratorios Farmaceuticos S.A.
Migraine
Study to Assess the Real-World Effectiveness of Ubrogepant in Adult Participants When Treating During the Prodrome Phase of Migraine Attacks
Migraine is a neurological disease characterized by moderate or severe headaches, associated with nausea, vomiting, and/or sensitivity to light and sound.
- Trial name
- PHASES (NCT07310290)
- Where
- 3 sites in United States
- Volunteers
- 189 people
- Sponsor
- AbbVie
Migraine Headaches
To Evaluate the Safety and Efficacy of Trexima in the Acute Treatment of Migraine Headaches
To determine the efficacy of the Trexima versus placebo as assessed by pain relief and the incidences of photophobia, phonophobia and nausea at 2 hours after treatment as the primary endpoints.
- Trial name
- NCT00433732
- Testing
- sumatriptan, naproxen sodium
- Where
- 2 sites in United States
- Volunteers
- 1,400 people
- Sponsor
- POZEN
Migraine
A Study to Learn About Zavegepant as a Treatment for Multiple Migraine Attacks in Adult Participants
The purpose of this study to show that zavegepant 10 milligrams given through the nose provides: freedom from pain, 2 hours after taking the medicine for the first migraine attack.
- Trial name
- NCT06103734
- Testing
- Zavegepant 10 mg
- Sponsor
- Pfizer
Migraine
Safety and Efficacy Study of MK0974 in the Acute Migraine (0974-016)
The purpose of this study is to investigate the efficacy and safety of MK0974 compared to a placebo for acute migraine.
- Trial name
- NCT00432237
- Testing
- MK0974 50 mg, MK0974 150 mg, MK0974 300 mg
- Volunteers
- 1,703 people
- Sponsor
- Merck Sharp & Dohme LLC
Migraine Disorders, Migraine, Acute
TREXIMET® Versus Butalbital-containing Combination Medications for the Acute Treatment of Migraine in Adults
Study TRX109011/TRX109013, A Randomized, Double-blind, Double-dummy, Placebo-controlled, Crossover Study to Evaluate the Efficacy of TREXIMET® (Sumatriptan + Naproxen Sodium) versus Butalbital-containing Combination Medications…
- Trial name
- NCT00573170
- Testing
- TREXIMET®, Butalbital-containing Combination Medications (BCM)
- Where
- 107 sites in United States
- Volunteers
- 375 people
- Sponsor
- GlaxoSmithKline
Migraine
Multimechanistic Treatment Over Time of Migraine Symptoms (MOVEMENT)
MOVEMENT (Multimechanistic Treatment over Time of Migraine Symptoms) is a Phase 3 study to evaluate the long-term safety of chronic intermittent use of AXS-07 and to assess the effect of AXS-07 on migraine symptoms following…
- Trial name
- NCT04068051
- Testing
- AXS-07
- Where
- 51 sites in United States
- Volunteers
- 706 people
- Sponsor
- Axsome Therapeutics, Inc.
Acute Migraine
A Long-Term Safety Study of Elismetrep (K-304) in the Acute Treatment of Migraine
This is a long-term safety study to evaluate the safety and tolerability of intermittent use of elismetrep in the acute treatment of migraine attacks.
- Trial name
- NCT07674654
- Testing
- Elismetrep
- Where
- 113 sites in United States
- Volunteers
- 1,000 people
- Sponsor
- TriGemX Bio, Inc.